JP2016528217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528217A5 JP2016528217A5 JP2016529868A JP2016529868A JP2016528217A5 JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5 JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- nucleoside analog
- combination
- taxane
- activated prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 claims 10
- 230000007954 hypoxia Effects 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229940123237 Taxane Drugs 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 239000002777 nucleoside Substances 0.000 claims 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 7
- 229960001592 paclitaxel Drugs 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361859152P | 2013-07-26 | 2013-07-26 | |
| US61/859,152 | 2013-07-26 | ||
| US201361887873P | 2013-10-07 | 2013-10-07 | |
| US61/887,873 | 2013-10-07 | ||
| US201461994295P | 2014-05-16 | 2014-05-16 | |
| US61/994,295 | 2014-05-16 | ||
| PCT/US2014/047885 WO2015013448A1 (en) | 2013-07-26 | 2014-07-23 | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528217A JP2016528217A (ja) | 2016-09-15 |
| JP2016528217A5 true JP2016528217A5 (https=) | 2017-08-31 |
Family
ID=51299053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529868A Pending JP2016528217A (ja) | 2013-07-26 | 2014-07-23 | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160158253A1 (https=) |
| EP (1) | EP3024490A1 (https=) |
| JP (1) | JP2016528217A (https=) |
| CN (1) | CN105792845A (https=) |
| WO (1) | WO2015013448A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017192863A1 (en) | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| CN106279321A (zh) * | 2016-08-09 | 2017-01-04 | 南京医科大学 | 吉西他滨ProTide乏氧活化前药及其应用 |
| JP6975230B2 (ja) * | 2016-10-05 | 2021-12-01 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 患者モニタリングシステム及び方法 |
| WO2019183623A1 (en) * | 2018-03-23 | 2019-09-26 | Adenocyte Llc | Method to induce exfoliation of cells and/or tissue fragments for enhanced cytopathologic cell collection |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| JP2024531479A (ja) | 2021-08-27 | 2024-08-29 | アセンタウィッツ ファーマシューティカルズ リミテッド | 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| US20250295677A1 (en) | 2022-04-15 | 2025-09-25 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| WO2024061346A1 (zh) | 2022-09-22 | 2024-03-28 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| TW202434258A (zh) | 2023-02-27 | 2024-09-01 | 大陸商深圳艾欣達偉醫藥科技有限公司 | 溶液、凍乾製劑、凍乾製劑單位包裝、注射液及注射液配製方法 |
| AU2024317010A1 (en) | 2023-07-28 | 2026-02-26 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPH07505887A (ja) * | 1992-04-17 | 1995-06-29 | アボツト・ラボラトリーズ | タキソール誘導体 |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| NZ521851A (en) | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| US7629332B2 (en) | 2003-10-31 | 2009-12-08 | Auckland Uniservices Limited | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
| CN102746336B (zh) | 2005-06-29 | 2015-08-19 | 施瑞修德制药公司 | 氨基磷酸酯烷化剂前体药物 |
| EP1931769A2 (en) | 2005-10-03 | 2008-06-18 | Genetix Pharmaceuticals Inc. | Method for selectively depleting hypoxic cells |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| JP5765634B2 (ja) * | 2008-10-21 | 2015-08-19 | スレッシュホールド ファーマシューティカルズ， インコーポレイテッド | 低酸素活性化型プロドラッグを用いるがんの処置 |
| BR112012030909A2 (pt) * | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| CA2803113A1 (en) | 2010-06-28 | 2012-01-12 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
| WO2012009288A2 (en) | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| JP2014509658A (ja) * | 2011-04-01 | 2014-04-21 | スレッショルド ファーマシューティカルズ、インク． | ガン処置方法 |
| KR20140045931A (ko) | 2011-04-15 | 2014-04-17 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 경구 투여를 위한 단위투여량 형태 |
| WO2013096687A1 (en) | 2011-12-22 | 2013-06-27 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer |
| EP2793899A4 (en) | 2011-12-22 | 2015-06-17 | Threshold Pharmaceuticals Inc | HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT |
| US20160045522A1 (en) | 2012-02-21 | 2016-02-18 | Threshold Pharmaceuticals, Inc. | Treatment of Cancer |
-
2014
- 2014-07-23 US US14/907,190 patent/US20160158253A1/en not_active Abandoned
- 2014-07-23 WO PCT/US2014/047885 patent/WO2015013448A1/en not_active Ceased
- 2014-07-23 CN CN201480053041.5A patent/CN105792845A/zh active Pending
- 2014-07-23 JP JP2016529868A patent/JP2016528217A/ja active Pending
- 2014-07-23 EP EP14748448.9A patent/EP3024490A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528217A5 (https=) | ||
| IL254377B (en) | Selective akr1c3 reductase activated prodrugs and their use for treating cancer patients | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
| HK1216853A1 (zh) | 治療胰腺癌的方法 | |
| HUE055873T2 (hu) | Arany klaszter (AuCs) vagy AuCs-t tartalmazó anyagok alkalmazása glaukóma megelõzésére és/vagy kezelésére szolgáló gyógyszer elõállítására | |
| JP2014141525A5 (https=) | ||
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| HK1255141A1 (zh) | 包含抗folr1免疫缀合物的治疗组合 | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| HUE044317T2 (hu) | Szubsztituált 2-tioxo-imidazolin-4-on vegyületek és spiro-analógjaik, rákellenes alkotórész, gyógyászati készítmény, orvosi preparátum, eljárás prosztatarák kezelésére | |
| JP2018522028A5 (https=) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| HUE063047T2 (hu) | Rákellenes gyógyszerkészítmények kombinált terápiához | |
| IL267775A (en) | Combined treatment with a Lantrin-1 interfering drug and immune checkpoint inhibitor drugs | |
| HUE066216T2 (hu) | Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| CY1123539T1 (el) | Παραγων κατα των ογκων που περιλαμβανει ενυδρη υδροχλωρικη ιρινοτεκανη | |
| MA43178A (fr) | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci | |
| EP3365026A4 (en) | ANTICIPATING AND INFLAMMATORY THERAPEUTICS AND METHOD THEREFOR | |
| HUE047272T2 (hu) | Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére | |
| JP2019518052A5 (https=) |